SGAM
ACOR

Smith Group Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Smith Group Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-71
Closed -$226K – 517
2016
Q1 		$226K Buy
+71
New +$295K 0.01% 201
2015
Q2 		– Sell
-226
Closed -$902K – 438
2015
Q1 		$902K Sell
226
-18
-7% -$82.4K 0.03% 177
2014
Q4 		$1.2M Buy
+244
New +$1.05M 0.04% 173

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Smith Group Asset Management's ACOR Position: Q2 2016 in Review

Smith Group Asset Management sold out of Acorda Therapeutics (ACOR) in Q2 2016, closing a stake of 71 shares — an estimated $226K sold.

Smith Group Asset Management first reported a position in ACOR in Q4 2014 and held it in 3 quarters. The position peaked at $1.2M in Q4 2014. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2016.

  • Smith Group Asset Management reported no remaining Acorda Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Smith Group Asset Management sold 71 Acorda Therapeutics shares in Q2 2016, an estimated $226K.
  • Smith Group Asset Management first reported a position in Acorda Therapeutics in Q4 2014 and held it in 3 quarters.
  • Smith Group Asset Management's Acorda Therapeutics position peaked at $1.2M in Q4 2014.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2016.

Based on Smith Group Asset Management's 13F filing for Q2 2016, filed 26 Jul 2016.